Hematology Xagena
Treatment of polycythemia vera aims to prevent thromboembolic complications, reduce the risk of progression to acute leukemia or myelofibrosis, and ameliorate the symptom burden; specifically, to impr ...
Brexucabtagene autoleucel ( KTE-X19; Brexu-cel; Tecartus ) is an autologous anti-CD19 chimeric antigen receptor ( CAR ) T-cell therapy approved for the treatment of patients with relapsed / refractory ...
Teclistamab is a BCMA × CD3 T-cell redirecting bispecific antibody under investigation in patients with relapsed / refractory multiple myeloma ( RRMM ). Daratumumab ( Darzalex Faspro) is a CD38 mono ...
Belantamab mafodotin ( Belamaf; Blenrep ), a B-cell maturation antigen ( BCMA ) targeted antibody-drug conjugate approved for adult patients with relapsed / refractory multiple myeloma, has a multimod ...
The results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center have shown that first-line treatment with Axicabtagene ciloleucel ( Axi-cel; Yescarta ), a ch ...
On the basis of the DREAMM-2 study, single-agent Belantamab mafodotin ( Belamaf; Blenrep ) was approved for patients with relapsed or refractory multiple myeloma ( RRMM ) who received 4 or more prior ...
In patients with transplant-ineligible newly diagnosed multiple myeloma ( NDMM ), Daratumumab ( Darzalex ) has reduced the risk of disease progression or death by 44% in MAIA ( Daratumumab / Lenalidom ...
A phase 1-2 study evaluated Brentuximab vedotin ( Adcetris ) combined with Nivolumab ( Opdivo ) as first salvage therapy in patients with relapsed/refractory ( r/r ) classical Hodgkin lymphoma ( cHL ...
Myelofibrosis symptoms compromise health-related quality of life ( HRQoL ). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue Ruxolitinib due to loss of response or ...
Low-density lipoprotein ( LDL ) receptor-related protein-associated protein 1 ( LRPAP1 ) had been identified by B-cell receptor ( BCR ) expression cloning and subsequent protein array screening as a f ...
Tafasitamab, an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug Lenalidomide ( Revlimid ), was clinically active with a good tolerability profile in the ...
Low-density lipoprotein ( LDL ) receptor-related protein-associated protein 1 ( LRPAP1 ) had been identified by B-cell receptor ( BCR ) expression cloning and subsequent protein array screening as a f ...
Early recognition of Ph-like acute lymphoblastic leukemia cases could impact on the management and outcome of this subset of B-lineage ALL. To assess the prognostic value of the Ph-like status in ...
Mediastinal gray zone lymphoma ( MGZL ) is a rare form of non-Hodgkin lymphoma ( NHL ) with intermediate features between classical Hodgkin lymphoma ( cHL ) and primary mediastinal B-cell lymphoma ( P ...
Bortezomib, Lenalidomide, Dexamethasone plus transplant is a standard of care for eligible multiple myeloma patients. As responses can deepen with time, regimens with longer and more potent inductio ...
